Glaukos Corporation (NYSE:GKOS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Glaukos Corporation (NYSE:GKOS) have earned a consensus rating of “Moderate Buy” from the sixteen analysts that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $117.2308.

A number of research firms recently weighed in on GKOS. Stifel Nicolaus set a $115.00 target price on shares of Glaukos in a research report on Monday, October 27th. Piper Sandler restated an “overweight” rating and issued a $61.00 price objective on shares of Glaukos in a report on Wednesday, December 17th. Stephens lifted their target price on Glaukos from $115.00 to $145.00 and gave the company an “overweight” rating in a research report on Friday. BTIG Research reiterated a “buy” rating and set a $116.00 target price on shares of Glaukos in a report on Friday. Finally, The Goldman Sachs Group started coverage on Glaukos in a research report on Wednesday, October 1st. They set a “buy” rating and a $103.00 price target for the company.

Insider Activity

In related news, CFO Alex R. Thurman sold 315 shares of the firm’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $105.00, for a total value of $33,075.00. Following the completion of the transaction, the chief financial officer directly owned 50,488 shares of the company’s stock, valued at approximately $5,301,240. This trade represents a 0.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gilbert H. Kliman sold 5,000 shares of the business’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $107.27, for a total transaction of $536,350.00. Following the transaction, the director owned 34,905 shares in the company, valued at approximately $3,744,259.35. The trade was a 12.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 24,655 shares of company stock valued at $2,310,025. 5.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Glaukos

Hedge funds have recently bought and sold shares of the stock. UMB Bank n.a. increased its stake in shares of Glaukos by 102.6% during the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 158 shares during the period. REAP Financial Group LLC acquired a new position in Glaukos in the 3rd quarter valued at $40,000. Park Place Capital Corp increased its position in Glaukos by 68.4% during the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 162 shares during the period. AlphaQuest LLC lifted its holdings in shares of Glaukos by 5,754.5% during the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after buying an additional 633 shares in the last quarter. Finally, SBI Securities Co. Ltd. lifted its holdings in shares of Glaukos by 42.9% during the third quarter. SBI Securities Co. Ltd. now owns 1,205 shares of the medical instruments supplier’s stock worth $98,000 after buying an additional 362 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Stock Down 1.7%

Shares of Glaukos stock opened at $110.94 on Friday. The firm has a market cap of $6.37 billion, a PE ratio of -72.04 and a beta of 0.67. The business’s 50 day simple moving average is $101.38 and its 200 day simple moving average is $94.73. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.47 and a current ratio of 5.20. Glaukos has a 52-week low of $73.16 and a 52-week high of $163.71.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11. The firm had revenue of $133.54 million during the quarter, compared to the consensus estimate of $122.55 million. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The business’s revenue was up 38.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.28) EPS. On average, analysts predict that Glaukos will post -1.08 earnings per share for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.